{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:34Z","timestamp":1792190494429,"version":"4.4.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UPMC Hillman Cancer Center CCSG","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R50CA211241"],"award-info":[{"award-number":["R50CA211241"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["S10OD0234402"],"award-info":[{"award-number":["S10OD0234402"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["S10OD032141"],"award-info":[{"award-number":["S10OD032141"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Pittsburgh Center for Research Computing and Data"},{"name":"HTC clusters"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["S10OD028483"],"award-info":[{"award-number":["S10OD028483"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancers that do not respond to immunotherapy typically harbor a non-T cell-inflamed tumor microenvironment (TME), characterized by the absence of type I\/II interferon signaling and CD8+ T cell infiltration. We previously reported IDH1 somatic mutations were enriched in this phenotype across histologies. Mutant IDH1 (mIDH1) drives immune exclusion via metabolic reprogramming of the TME, and preclinical models show that IDH inhibition can restore anti-tumor immunity. We conducted a Phase II study assessing the preliminary activity of ivosidenib, an IDH1 inhibitor, plus nivolumab, an anti-PD1 antibody, in patients with mIDH1 advanced solid tumors (NCT04056910).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with advanced or refractory mIDH1 solid tumors and no prior exposure to IDH1 inhibitor were administered ivosidenib 500\u2009mg by mouth daily with nivolumab 480\u2009mg intravenously every 4\u2009weeks. A composite primary endpoint included either six-month progression-free survival (PFS6) or overall response rate (ORR). Translational analyses incorporated pharmacodynamics, proteomics, and spatial transcriptomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen patients were enrolled (median age, 54\u2009years; female, 53.3%; ECOG 1, 60%; glioma, 46.7%; R132H, 40%). Three patients (20%) met the primary endpoint. Median PFS was 1.94\u2009months. The most common adverse events were leukopenia (67%), rash (67%), and diarrhea (33%). Treatment reduced plasma (R)-2HG, with greater reductions observed in patients who experienced clinical benefit. Exploratory serum proteomic and tumor spatial transcriptomic analyses suggested treatment-induced immune-modulatory effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ivosidenib plus nivolumab was safe with limited clinical benefit. Translational investigation highlights potential of IDH1 inhibition to alter tumor-immune interactions and provides hypotheses for future immune-checkpoint combinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf362","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:01:23Z","timestamp":1761393683000},"source":"Crossref","is-referenced-by-count":12,"title":["Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations"],"prefix":"10.1093","volume":"30","author":[{"given":"Matthew K","family":"Nguyen","sequence":"first","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jelinek","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Biostatistics Core, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Singh","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Cancer Bioinformatics Core, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Isett","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Cancer Bioinformatics Core, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica S","family":"Myers","sequence":"additional","affiliation":[{"name":"Health Sciences Mass Spectrometry Core, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Mullett","sequence":"additional","affiliation":[{"name":"Health Sciences Mass Spectrometry Core, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Eisele","sequence":"additional","affiliation":[{"name":"Health Sciences Sequencing Core, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H","family":"Beumer","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Pharmaceutical Sciences, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Johns Hopkins University , Baltimore, MD,","place":["USA"]},{"name":"Cancer Therapeutics Program, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Parise","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Urban","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rose","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Sellitto","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Singh","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Doerfler","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah E","family":"Dadey","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Kim","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Rhee","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-8055","authenticated-orcid":false,"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-523X","authenticated-orcid":false,"given":"Liza C","family":"Villaruz","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Burgess","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Drappatz","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mantica","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Neurology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E","family":"Goodman","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Biostatistics Core, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatur D","family":"Singhi","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Pathology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Translational Oncologic Pathology Services, UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J","family":"Luke","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan P","family":"Zandberg","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6105-1704","authenticated-orcid":false,"given":"Riyue","family":"Bao","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center , Pittsburgh, PA,","place":["USA"]},{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]},{"name":"Division of Malignant Hematology and Medical Oncology, University of Pittsburgh , Pittsburgh, PA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"2025111120321522300_oyaf362-B1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PPO.0b013e3181eacbd8","article-title":"Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy","volume":"16","author":"Gajewski","year":"2010","journal-title":"Cancer J"},{"key":"2025111120321522300_oyaf362-B2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","article-title":"Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment","volume":"25","author":"Gajewski","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"2025111120321522300_oyaf362-B3","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res"},{"key":"2025111120321522300_oyaf362-B4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","article-title":"Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types","volume":"12","author":"Bao","year":"2020","journal-title":"Genome Med"},{"key":"2025111120321522300_oyaf362-B5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10637-019-00771-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors","volume":"38","author":"Fan","year":"2020","journal-title":"Invest New Drugs"},{"key":"2025111120321522300_oyaf362-B6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025111120321522300_oyaf362-B7","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep.32424","article-title":"Biology of IDH mutant cholangiocarcinoma","volume":"75","author":"Wu","year":"2022","journal-title":"Hepatology"},{"key":"2025111120321522300_oyaf362-B8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025111120321522300_oyaf362-B9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J Clin Invest"},{"key":"2025111120321522300_oyaf362-B10","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2025111120321522300_oyaf362-B11","doi-asserted-by":"crossref","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"2025111120321522300_oyaf362-B12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH inhibits IFNgamma-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"2025111120321522300_oyaf362-B13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I study of the mutant IDH1 inhibitor ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025111120321522300_oyaf362-B14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.13-S2-27","article-title":"Other endpoints in screening studies for soft tissue sarcomas","volume":"13 Suppl 2","author":"Verweij","year":"2008","journal-title":"Oncologist"},{"key":"2025111120321522300_oyaf362-B15","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/cncr.29471","article-title":"Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the association des Gastro-Enterologues oncologues","volume":"121","author":"Brieau","year":"2015","journal-title":"Cancer"},{"key":"2025111120321522300_oyaf362-B16","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/annonc\/mdt391","article-title":"GDC-0449 in patients with advanced chondrosarcomas: a french sarcoma group\/US and french national cancer institute Single-Arm phase II collaborative study","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann Oncol"},{"key":"2025111120321522300_oyaf362-B17","doi-asserted-by":"crossref","first-page":"vi12","DOI":"10.1093\/neuonc\/now212.044","article-title":"Actr-46. AG120, a first-in-class mutant idh1 inhibitor in patients with recurrent or progressive idh1 mutant glioma: results from the phase 1 glioma expansion cohorts","volume":"18","author":"Mellinghoff","year":"2016","journal-title":"Neuro-Oncology"},{"key":"2025111120321522300_oyaf362-B18","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.2018.36.15_suppl.2002","article-title":"Phase 1 study of AG-881, an inhibitor of mutant IDH1\/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma","volume":"36","author":"Mellinghoff","year":"2018","journal-title":"JCO"},{"key":"2025111120321522300_oyaf362-B19","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025111120321522300_oyaf362-B20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2025111120321522300_oyaf362-B21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2025111120321522300_oyaf362-B22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"2025111120321522300_oyaf362-B23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med"},{"key":"2025111120321522300_oyaf362-B24","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nat Cancer"},{"key":"2025111120321522300_oyaf362-B25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat Med"},{"key":"2025111120321522300_oyaf362-B26","first-page":"A576","article-title":"552 Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial","volume":"10(Suppl 2)","author":"Duygu Saatcioglu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025111120321522300_oyaf362-B27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025111120321522300_oyaf362-B28","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1-Mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025111120321522300_oyaf362-B29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025111120321522300_oyaf362-B30","doi-asserted-by":"crossref","first-page":"TPS4197","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4197","article-title":"A phase 1\/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma","volume":"42(16_suppl)","author":"Kelley","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf362\/64943948\/oyaf362.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf362\/64943948\/oyaf362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf362\/64943948\/oyaf362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:32:25Z","timestamp":1762911145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf362\/8301303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf362","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,25]]},"article-number":"oyaf362"}}